drug
dacomitinib
Marketedupdated 4mo agoby $PFE PFIZER INC
Approvedcommunity read0 votes
indications
investigational
NSCLC
all catalysts(0)
nothing on the calendar yet
Trials studying dacomitinib
- —Korea Post Marketing Surveillance (PMS) Study of Vizimpro
- phase2Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC
- phase2Phase 2 Study of Dacomitinib in NSCLC
- —Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
- —Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice)
- —A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.
- phase4Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
- phase2The Drug Rediscovery Protocol (DRUP Trial)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 27, 2032
~6.1 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (9)
- Sep 27, 2032compositionUS 7772243
- Sep 27, 2032compositionUS 7772243
- Sep 27, 2032compositionUS 7772243
- Feb 2, 2026method-of-use (U-3338)US 10596162
- Feb 2, 2026method-of-use (U-3338)US 10596162
- Feb 2, 2026method-of-use (U-3338)US 10596162
- Feb 2, 2026method-of-use (U-3337)US 10603314
- Feb 2, 2026method-of-use (U-3337)US 10603314
- Feb 2, 2026method-of-use (U-3337)US 10603314
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that